Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against PLD1
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intravitreal
01
Overview
siRNA against PLD1 (phospholipase D1) is a research-use-only small interfering RNA designed to silence the expression of the PLD1 gene. Phospholipase D1 is an enzyme that catalyzes the hydrolysis of phosphatidylcholine to generate phosphatidic acid, a key lipid second messenger involved in membrane remodeling, vesicle trafficking, and cell signaling. In laboratory research, PLD1 siRNA is widely utilized to investigate the role of PLD1 in various cellular processes, including cell proliferation, migration, exosome secretion, and inflammatory responses, particularly in cancer cell lines (such as breast cancer and melanoma) and inflammatory disease models.
- Other names
- PLD1 siRNAPLD-1 siRNAPLD 1 siRNAsiRNA-pld1siRNA-pld-1siRNA-pld 1
02
Targets
PLD1 (Phospholipase D1)
Beyond the preview
Go deeper on siRNA against PLD1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA against PLD1.